Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPJ005 in Patients With ATR-X Syndrome
jRCT2051220062Active, not recruiting
- Sponsor
- Not applicable
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of NPJ005 in Alpha thalassemia X-linked intellectual disability syndrome (ATRX), sponsored by Not applicable. Primary endpoints: Safety (adverse events and side effects), Developmental assessment (new version of K-type developmental test) and 1 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
NPJ005
03
Conditions
Alpha thalassemia X-linked intellectual disability syndrome (ATRX)
Beyond the preview
Go deeper on jRCT2051220062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220062.